Pulsar-18 T3 Peripheral Self-Expanding Nitinol Stent System
Biotronik AG · Decision date Sep 11, 2026
What did the FDA decide?
The FDA record for P160025/S026, dated 2026-09-11 and marked OK30, is a 30-day notice supplement to the Pulsar-18 T3 Peripheral Self-Expanding Nitinol Stent System PMA. The listed change is "modifications to the Gold-plating manufacturing equipment" and is categorized as a process change involving a manufacturer, sterilizer, packager or supplier. The stent's device category is superficial femoral artery stent (product code NIP, cardiovascular specialty), with Biotronik AG as applicant.
The S026 supplement number ties this filing to the original P160025 approval, but it does not constitute approval of the whole stent system, and a manufacturing notice is not an original PMA. The record states a purpose — equipment modification — without specifying which equipment, what the modifications were, or any supporting validation. The database entry provides no evidence of safety or clinical effectiveness; that reported purpose should not be read as such proof.
Several details remain absent: the equipment's identity, the nature and extent of the modification, the affected manufacturing step, and any performance data. Researchers should treat the entry as a notice of a process change and not infer an indication change, a trial, or a clinical outcome.
FDA approval order statement
modifications to the Gold-plating manufacturing equipment
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 11, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P160025/S026
- Regulatory pathway
- PMA supplement
- Applicant
- Biotronik AG
- Product code
- NIP
- Decision code
- OK30
- Decision date
- Sep 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: STENT, SUPERFICIAL FEMORAL ARTERY.
- Applicant
- Biotronik AG
- Product code
- NIP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P160025. Subsequent supplements may change the device or its indications.
FDA decision timeline
P160025 · Original PMA
ASTRON PULSAR STENT SYSTEM, PULSAR-18 STENT SYSTEM
P160025/S026 received
Application receipt date recorded by FDA.
P160025/S026 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P160025. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160025
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik AG | PMA approval | Mar 23, 2017 | FDA |
Explore the linked device profile
Other records with product code NIP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Supera Peripheral Stent SystemP120020/S037 | Abbott Vascular (Idef Technologies Inc) | PMA supplement | Nov 6, 2026 | FDA |
| Medtronic Vascular, Inc. | PMA supplement | Nov 5, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Cordis US Corporation | PMA supplement | Oct 15, 2026 | FDA | |
| Abbott Vascular (Idef Technologies Inc) | PMA approval | Mar 28, 2014 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik AG
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Ackerstrasse 6, Bülach, 8180
Sources and methodology
- Original FDA record: P160025/S026
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



